Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

7.32
-0.1700-2.27%
Post-market: 7.320.00000.00%17:39 EDT
Volume:398.56K
Turnover:2.93M
Market Cap:396.13M
PE:-3.21
High:7.63
Open:7.63
Low:7.26
Close:7.49
Loading ...

Zevra to Participate at Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM

TIPRANKS
·
10 Feb

Zevra Therapeutics price target raised to $21 from $20 at Guggenheim

TIPRANKS
·
04 Feb

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

Simply Wall St.
·
17 Jan

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

Simply Wall St.
·
27 Dec 2024

Zevra Therapeutics to Join Nasdaq Biotechnology Index

MT Newswires Live
·
17 Dec 2024

Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: Nbi) Effective December 23, 2024

THOMSON REUTERS
·
17 Dec 2024

BRIEF-Zevra Therapeutics Announces Organizational Changes

Reuters
·
07 Dec 2024

Zevra Therapeutics Restructures to Focus on Rare Diseases

TIPRANKS
·
07 Dec 2024

Zevra Therapeutics announces departure of CDO Christal Mickle, CSO Sven Guenther

TIPRANKS
·
07 Dec 2024

Zevra Therapeutics Inc - to Close Laboratory Facilities in Iowa and Virginia

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Announces Organizational Changes

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Consolidates Development and Scientific Functions Under Cmo Adrian Quartel

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Christal M.m. Mickle, Chief Development Officer, and Sven Guenther, Ph.d., Chief Scientific Officer, to Depart Co

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Eliminates Positions in Chemistry, Manufacturing and Controls and Clinical Development

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Zevra Has Discontinued Its in-House Drug Discovery Activities

THOMSON REUTERS
·
07 Dec 2024